Annoroad, Illumina Agree To Co-Develop NGS System For Reproductive Health

(RTTNews) - Annoroad, an enterprise in the genomic industry in China, and Illumina, Inc. (ILMN) have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation sequencing or NGS technology.

NGS technology has evolved rapidly in recent years and is regarded as an essential factor for enabling precision medicine.

The collaboration between Annoroad and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market. The two companies will work together to develop a user-friendly, prenatal DNA diagnostic system for the Chinese market.

The collaboration will bring together technology from Illumina sequencers with Annoroad's advanced clinical application development capabilities.

As part of the agreement, Annoroad will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.